Peginterferon alfa-2b

Quick links

Choose a section

Quick links to important sections

Advertisements

Peginterferon alfa-2b

Selected form

Advertisements
Advertisements

Overview of Peginterferon alfa-2b

Quick Facts

Property Description
Active ingredient Peginterferon alfa-2b (INN)
Form Powder for solution for injection
Pharmacological class Pegylated Interferon-Alpha (PEG-IFN-α), Immunoregulatory Drug
Origin Recombinant/Synthetic Biologic
Route of administration Subcutaneous injection

What Type of Medicine is Peginterferon alfa-2b?

Peginterferon alfa-2b is a highly specialized biologic agent classified as a Pegylated Interferon-Alpha (PEG-IFN-α), an important drug class of antiviral agents and immunoregulatory drugs. This substance belongs to the alpha interferon family, which comprises proteins that serve a crucial signaling role in the body's defensive communication system. The drug itself is defined as a recombinant/synthetic biologic because the core protein, the interferon alfa-2b moiety, is manufactured using recombinant DNA technology. Peginterferon alfa-2b acts as a sustained immunostimulant. This classification establishes it as a powerful, specialized tool designed to modulate the immune system and combat persistent biological threats within the body.

What is Peginterferon alfa-2b Made Of? (Composition and Form)

Peginterferon alfa-2b is a single-entity product that is a covalent conjugate of the active protein and a large synthetic polymer, monomethoxy polyethylene glycol (PEG). The chemical process of pegylation binds the PEG moiety to the interferon alfa-2b moiety, creating the full Peginterferon alfa-2b compound with unique properties. This chemical modification significantly slows the drug’s elimination from the body, leading to its sustained action. This specialized composition is beneficial because it allows the medicine to remain effective for longer periods. The medicine is typically supplied as a lyophilized powder for injection, which is reconstituted into an aqueous solution for subcutaneous injection.

What is the General Purpose of this Immunoregulatory Drug?

The general purpose of Peginterferon alfa-2b is to initiate and sustain the body's innate antiviral response, providing critical support to the immune system. It works by acting as a powerful immunostimulant, binding to specific receptors on cells to induce powerful physiological actions such as the inhibition of virus replication and the suppression of cell proliferation. While Peginterferon alfa-2b is often cited for its role in treating conditions involving chronic viral infection, its primary differentiating factor is its prolonged duration of action achieved through pegylation, making it a highly valued antiviral agent in long-term treatment protocols.

Regulatory References

  1. Interferon Alfa-2b Injection: MedlinePlus Drug Information
Advertisements

What side effects are possible with Peginterferon alfa-2b?

Possible Side Effects and Safety Information

The official safety information for Peginterferon alfa-2b is characterized by a high frequency of systemic effects and documented risks spanning multiple organ systems, as defined in regulatory classifications (e.g., EMA SmPC, FDA Prescribing Information).

Frequency Classification and Systemic Effects

Adverse reactions are classified by frequency based on clinical reporting. Very common (ge 1/10) effects typically include flu-like symptoms (such as fever, rigors, headache, fatigue, myalgia, and arthralgia), injection site reactions, and neuropsychiatric disturbances like depression, insomnia, and irritability. Common (ge 1/100 to < 1/10) effects include anaemia, neutropenia, thyroid disorders, anxiety, dizziness, and gastrointestinal symptoms like nausea and diarrhoea.

Serious Adverse Reactions and Restrictions

Regulatory documents highlight the potential for serious adverse reactions, particularly severe neuropsychiatric disorders (including severe depression and suicidal ideation/attempts), cardiovascular events (arrhythmias, cardiomyopathy), pulmonary disorders (interstitial pneumonitis), and severe ocular effects (retinopathy).

The safety profile includes specific limitations. The medicine is contraindicated for individuals with a history of severe psychiatric conditions or decompensated liver disease. Safety notes indicate that flu-like symptoms are often more pronounced at the start of treatment, while risks of neutropenia and some severe organ effects may increase with long-term exposure.

Population-Specific Safety

Official labels advise that patients with pre-existing cardiac disease or autoimmune conditions face an increased risk of adverse events, requiring careful consideration before use.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose Scope and Manifestations

There is limited official documentation on the effects of acute, massive overdosage of Peginterferon alfa-2b in humans. The anticipated clinical manifestations of an acute overdose are generally expected to be a direct exaggeration of the drug's established, dose-related adverse effects.

Overdose has been associated with more frequent and severe clinical outcomes, including profound myelosuppression (severe decreases in white blood cell and platelet counts), neuropsychiatric disturbances, and potentially cardiovascular events.

Overdose Presentation (Expected) Management Principle
Severe flu-like symptoms, fatigue Supportive and symptomatic care
Profound cytopenias (low blood counts) Close monitoring; possible blood transfusions
Neuropsychiatric events (e.g., psychosis) Discontinuation and specialized intervention

Immediate Action and Emergency Guidance

In the event of a suspected or confirmed overdose, seek emergency medical attention immediately. Contact a poison control center or emergency services right away. Official regulatory guidance emphasizes that overdose management is supportive. This means treatment should focus on managing the symptoms and complications that arise. There is no specific antidote for Peginterferon alfa-2b overdose. Immediate actions include discontinuing the drug and instituting supportive medical measures, close patient observation, and monitoring of laboratory parameters, such as complete blood counts, for a prolonged period.

Advertisements

Therapeutic Uses of Peginterferon alfa-2b

What Peginterferon alfa-2b Treats: Main Uses and Benefits

Peginterferon alfa-2b is a specialized immunoregulatory drug used in clinical settings that require specialized, long-term therapeutic support against persistent disease threats. Its primary therapeutic domains involve two distinct areas: managing chronic viral infection and management of the risk of cancer recurrence.

Peginterferon alfa-2b is commonly used to help with conditions characterized by periods of heightened symptoms related to chronic disease and high-risk relapse. This medication is applied in addressing the chronic, continuous presence of the Hepatitis C Virus (HCV) and is relevant as adjuvant therapy following the definitive surgical removal of high-risk malignant melanoma that has spread to the lymph nodes.

Targeting Persistent Disease Threats

In the context of Hepatitis C, the therapeutic approach is considered relevant for the clinical measure known as a Sustained Virologic Response (SVR). By addressing this viral persistence, the medicine may assist with the management of progressive liver damage, such as advanced fibrosis and compensated cirrhosis, and contributes to easing the long-term risk associated with the infection's progression.

“This supportive therapeutic approach helps maintain a sense of stability during challenging, high-risk phases of disease management.”

For high-risk melanoma, the supportive use helps maintain a sense of stability by contributing to the delay of relapse of the melanoma, providing supportive relief in a high-risk clinical scenario.


Quick Fact: Relief for Chronic Viral Activity
Peginterferon alfa-2b is used for managing symptom clusters related to the chronic presence of Hepatitis C and high-risk recurrence in melanoma, providing supportive relief that contributes to easing the overall symptomatic load.

Regulatory References

  1. NIH MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

Peginterferon alfa-2b is a highly specialized medication, and its use is strictly governed by official population eligibility rules defined in regulatory documents.

Populations Who Must Not Use the Medicine (Contraindications)

The medicine is formally prohibited for patients with a history of autoimmune hepatitis, severe psychiatric disorders (such as severe depression or suicidal ideation), or decompensated liver disease (Child-Pugh score greater than 6). It is also contraindicated in patients with severe pre-existing cardiovascular disease or an uncontrolled thyroid condition. Infants and neonates are excluded due to excipient content in some formulations.

Age- and Condition-Based Eligibility

The medicine is approved for adults for both Chronic Hepatitis C (CHC) and adjuvant melanoma therapy. For CHC, it is approved for pediatric patients aged 3 years and older who have compensated liver disease. Use for the melanoma indication is not established in patients under 18 years of age. Patients with severe renal impairment may be eligible but are restricted to a lower, adjusted dose.

Pregnancy and Reproductive Restrictions

Use is not recommended during pregnancy or lactation. Regulatory labeling requires both male and female patients of reproductive potential to use effective contraception during and for a period following treatment.

Advertisements

What should I know about interactions with other medicines?

Peginterferon alfa-2b’s official interaction profile is structured around specific pharmacokinetic and pharmacodynamic constraints documented in regulatory labeling.

Pharmacokinetic Interactions

The medicine requires caution when co-administered with drugs that are primarily metabolized by Cytochrome P450 isoenzymes CYP2C9 or CYP2D6, recognizing a potential for altered plasma concentrations of these co-administered drugs. Examples include warfarin, phenytoin, and flecainide. Monitoring is also necessary with methadone due to the potential for an increased narcotic effect.

Pharmacodynamic and Administration Constraints

The profile includes several constraints:

  • Nucleoside Analogues: Close observation is required for worsening toxicities when co-administered with Nucleoside Analogues, including Ribavirin. Co-administration of co-administered Ribavirin with Didanosine is not recommended.
  • Live Vaccines: Combination with Live Vaccines is not recommended due to the drug’s immunoregulatory effects.
  • Procedural Constraint: When used in combination therapy, the accompanying drug Ribavirin must be administered with food.

Population-Specific Notes

The drug’s own elimination clearance is reduced by approximately half in individuals with severe renal impairment (creatinine clearance less than 50 mL/minute), which is a key population constraint affecting overall drug exposure.

Advertisements

Mechanism of Action

Receptor Binding and JAK/STAT Pathway Activation

Peginterferon alfa-2b acts as a pro-drug that releases the active interferon alfa-2b moiety. This protein directly targets and binds to the Type 1 Interferon Receptors (IFNAR1/2) found on most host cell surfaces, functioning as an agonist. This binding initiates the Janus Kinase/STAT (JAK/STAT) signaling pathway inside the cell.

This molecular cascade leads to the transcription of hundreds of Interferon-Stimulated Genes (ISGs), which alters the cell’s transcriptional profile and modulates processes related to growth and survival.

Synthesis of Effector Proteins and Immunomodulation

The resulting ISGs synthesize specific effector proteins, such as Protein Kinase R (PKR) and 2'5' Oligoadenylate Synthetase, which functionally interferes with the machinery required for viral replication. Concurrently, the mechanism augments the functional capacity of specific immune cells, including Natural Killer (NK) cells and macrophages, which contributes to systemic immune modulation.

Modulation of Cell Proliferation and Apoptosis

Pathways activated by the drug modulate cell proliferation, resulting in cell cycle arrest and induction of programmed cell death (apoptosis) in susceptible cells. The mechanism's sustained action is tempered by the hydrolysis of the PEG bond, limiting the duration of the active moiety, and its overall physiological response is influenced by host genetic factors like the IFNL3 genotype, which determines the maximal magnitude of the induced signaling cascade.

Advertisements

Dosage and Administration Information

Peginterferon alfa-2b is administered as a once-weekly subcutaneous injection. The injection should be given on the same day each week to maintain a consistent dosing schedule. The dosage is highly specific, being weight-based (micrograms per kilogram or mcg/kg) for adults with Chronic Hepatitis C (CHC) and melanoma, or body surface area-based (micrograms per meter squared or mcg/m^2) for pediatric CHC patients 3 years of age and older.


Administration Details

Classification Rule
Route of Administration Subcutaneous injection.
Frequency Pattern Once weekly, on the same day of the week.
Special Conditions Injection sites must be rotated. Do not inject into areas that are sore, red, bruised, or scarred.
Preparation Lyophilized powder must be reconstituted with Sterile Water for Injection, USP. Swirl gently; do not shake. Visually inspect the solution before use; discard if discolored, cloudy, or contains particulates.

Official Dosing Rules (Select Examples)

  • Melanoma (Adjuvant): A starting dose of 6 mcg/kg/week for the first 8 doses, followed by 3 mcg/kg/week for up to five years.
  • Chronic Hepatitis C (Combination Therapy, Adults): Recommended dose is 1.5 mcg/kg/week (in combination with ribavirin).
  • Combination with Ribavirin: If combination therapy with ribavirin capsules is used, ribavirin is administered orally twice daily with food (morning and evening).
  • Premedication (Melanoma): Premedication with 500 to 1000 mg of oral acetaminophen is recommended 30 minutes prior to the first dose, and as needed for subsequent doses.

The complex, weight-based dosing and mandated preparatory steps emphasize that treatment must be initiated and monitored only by a physician experienced in managing the patient's condition.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Peginterferon alfa-2b

Peginterferon alfa-2b was studied for its use in several conditions. Research contributes to the broader evidence landscape related to specific populations using organized clinical trials. This overview describes the structure of research, the patient groups studied, and the outcomes monitored.


Evidence for Use in High-Risk Malignant Melanoma

The clinical research for melanoma focused on its use as an adjuvant therapy, meaning it was evaluated after the main cancerous tissue was surgically removed. The evidence base is centered around a single, long-term, randomized controlled trial (RCT). This study included a treatment group and a no-treatment observation group.

The main outcome research examined was Relapse-Free Survival (RFS), which monitors the time elapsed from trial enrollment until recurrence of cancer. Findings related to Overall Survival (OS)—a measure of patient longevity tracked after trial enrollment—were mixed across different follow-up periods and analyses. A key limitation noted was a high rate of treatment discontinuation among patients due to effects observed during the regimen.


Evidence for Use in Chronic Hepatitis C (HCV) Infection

For chronic Hepatitis C, the medicine was studied for its role as part of a combination therapy—it was evaluated alongside other antiviral drugs, not by itself. The principal outcome the studies monitored was the Sustained Virologic Response (SVR). This measure tracks the status of detectable Hepatitis C Virus in the blood 24 weeks after the completion of therapy. Studies reported measurements of SVR in the Peginterferon alfa-2b combination group and compared them against measurements from the standard interferon combination group. However, the findings were observed in some studies to be genotype-specific, meaning outcomes were monitored in relation to differences based on viral genotype.


What is Still Uncertain About the Research Base

The evidence base, while structured by major trials, has areas where certainty remains low or where more research is ongoing. One major area of uncertainty is the long-term consistency of Overall Survival (OS) findings in the adjuvant melanoma setting. Additionally, for Myeloproliferative Neoplasms (MPNs), comparative evidence is lacking in the form of large Phase III trials against all alternative treatments. Across all indications, treatment discontinuation due to study-related events was observed in some studies, which limits the ability to draw conclusions about the effects of completing the full planned duration of therapy.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Peginterferon alfa-2b (FAQ)


Q: Is Peginterferon alfa-2b the same as other interferon medications?

Peginterferon alfa-2b is a specific form of interferon known as a pegylated interferon. Official sources describe this chemical modification (pegylation) as responsible for the drug’s prolonged half-life, which supports a less frequent dosing schedule compared to non-pegylated interferons.


Q: What is the difference between Peginterferon alfa-2b and standard Interferon alfa-2b?

The key difference is the addition of a polyethylene glycol (PEG) chain, which is chemically bound to the active interferon protein. This process results in a prolonged half-life, which is associated with a sustained therapeutic presence. Because of this, Peginterferon alfa-2b is typically dosed once weekly.


Q: Is Peginterferon alfa-2b safe for long-term use?

The approved regimen for adjuvant melanoma therapy is described in official documentation as lasting up to five years. However, regulatory warnings note that the risk of certain side effects, such as a low white blood cell count (neutropenia), may increase with long-term exposure.


Q: Does Peginterferon alfa-2b have an effect on fertility or pregnancy?

According to official product information, the use of Peginterferon alfa-2b is not recommended during pregnancy or while breastfeeding. Regulatory guidance also requires both male and female patients of reproductive potential to use effective contraception during treatment and for a specified period after the final dose.


Q: What food or drinks should I avoid while using Peginterferon alfa-2b?

Regulatory documents do not list specific food or drink restrictions for Peginterferon alfa-2b when used alone. However, if the medicine is used as part of a combination therapy that includes the drug ribavirin, official guidance states that the ribavirin companion medicine must be taken with food.


Q: What happens if I forget to use my Peginterferon alfa-2b dose?

If a dose is missed, regulatory patient guidance advises contacting a healthcare professional immediately for specific instructions. Guidance also advises against administering more than one injection within a single week to maintain the correct dosing schedule.


Q: What is the typical length of time a person uses Peginterferon alfa-2b?

The duration of treatment depends on the condition. For adjuvant melanoma therapy, the regimen is described as lasting up to five years. For Chronic Hepatitis C, treatment courses are typically described as lasting for 24 or 48 weeks, depending on the viral type (genotype) and the patient’s clinical response.


Q: Is Peginterferon alfa-2b considered an immunosuppressant?

No, Peginterferon alfa-2b is classified as an immunoregulatory drug and acts as an immunostimulant. Its mechanism involves modulating and augmenting the function of certain immune cells and inhibiting processes like virus replication and cell proliferation, which is the role of an immunostimulant.


Q: What is the role of Peginterferon alfa-2b in treating the conditions it's approved for?

The role of the medicine varies by indication. For melanoma, it is used as an adjuvant therapy, meaning it is given following the main surgical removal of the cancerous tissue. For Chronic Hepatitis C, it is used as part of a combination regimen alongside other antiviral medicines.


Q: Does Peginterferon alfa-2b interact with blood thinners?

Yes, regulatory labeling requires caution when this medicine is co-administered with certain drugs, including warfarin (a common blood thinner). This caution is necessary because Peginterferon alfa-2b may potentially alter the blood concentration of these co-administered medicines.


Q: Is Peginterferon alfa-2b affected by vaccination schedules?

Official documents note that co-administration with live vaccines is generally not recommended. This constraint is due to the drug’s effects on the immune system, which could potentially interfere with the effectiveness or safety of the vaccine.


Q: What is the storage requirement for Peginterferon alfa-2b before use?

Storage requirements depend on the product form. The lyophilized powder must be stored at room temperature, while the reconstituted solution and pre-filled pens must be stored in the refrigerator (between 2 C and 8 C), protected from light, and must not be frozen.


Q: Does Peginterferon alfa-2b cause hair loss?

Yes, in clinical trial data, hair loss (alopecia) is listed as a very common side effect. This is a potential effect that is explicitly documented in the official safety information for the medicine.


Q: Can Peginterferon alfa-2b affect my mood or mental health?

Yes, official safety information states that the medicine may cause or worsen neuropsychiatric disorders. This includes symptoms such as depression, anxiety, irritability, and suicidal ideation. Regulatory information emphasizes the importance of monitoring for any changes in mood or behavior.


Q: Is Peginterferon alfa-2b available in different strengths?

Yes, the product is typically supplied in a range of different strengths for injection (e.g., 50 mcg, 80 mcg, 120 mcg, 150 mcg). This variety of strengths supports the precise, individualized, and weight-based dosing requirements described in the official documents.


Q: Can Peginterferon alfa-2b affect my ability to drive or operate machinery?

Yes, the medicine may cause adverse effects like dizziness, drowsiness, and somnolence. Regulatory documents advise patients to use caution when operating machinery or driving if they experience these central nervous system effects.


Q: How is the effectiveness of Peginterferon alfa-2b measured in clinical trials?

Effectiveness is measured by specific clinical endpoints. For melanoma studies, the primary measure is typically Relapse-Free Survival (RFS). For Chronic Hepatitis C, the key measure is Sustained Virologic Response (SVR), which tracks if the virus is detectable in the blood 24 weeks after treatment is completed.


Q: Is Peginterferon alfa-2b a chemotherapy drug?

Peginterferon alfa-2b is classified as an alpha interferon and an immunoregulatory drug, not as a traditional cytotoxic chemotherapy drug. It works by modulating the immune system and inhibiting processes like cell proliferation.


Q: Can Peginterferon alfa-2b cause skin reactions at the injection site?

Yes, official safety information reports that injection site reactions are a very common side effect. These reactions can include redness, swelling, or pain at the area where the medicine is administered.


Q: Why is Peginterferon alfa-2b sometimes used with other medications?

When treating Chronic Hepatitis C, the medicine is used in combination regimens with other antiviral medications. Official studies indicated that combination therapy resulted in a sustained virologic response more frequently than treatment with the medicine alone.


Q: Can Peginterferon alfa-2b cause vision problems?

Yes, the medicine has been associated with severe ocular adverse reactions, including damage to the retina (retinopathy). This may potentially lead to visual disturbances, blurred vision, or, in rare cases, loss of vision.


Q: Is Peginterferon alfa-2b suitable for elderly patients?

The medicine is approved for use in adults, and formal studies have not identified major differences in safety or effectiveness between elderly and younger patients. However, caution is advised due to the higher likelihood of age-related decreases in kidney function.


Q: Are there any known severe allergic reactions associated with Peginterferon alfa-2b?

Yes, the medicine is contraindicated in patients with a history of severe systemic allergic reaction (anaphylaxis) to the drug. Post-marketing reports have included acute, severe hypersensitivity reactions, including anaphylactic shock.


Q: Does Peginterferon alfa-2b affect liver function?

Yes, the medicine has been associated with changes in liver enzymes (like ALT or AST) in some patients. It is strictly contraindicated for patients with pre-existing decompensated liver disease, and severe hepatic failure has been reported as a risk in some cases.


Q: Why might a person need to stop taking Peginterferon alfa-2b?

Regulatory guidelines define several criteria for permanent discontinuation. This may be due to persistent or worsening severe neuropsychiatric disorders, inability to tolerate a minimum dose, new or worsening retinopathy, or severe (Grade 4) non-hematologic toxicity that is not resolving.


Q: Are there specific symptoms that require immediate medical attention while on Peginterferon alfa-2b?

Official patient guidance instructs contacting a healthcare professional immediately if specific symptoms are experienced, particularly those related to severe gastrointestinal, cardiovascular, or neurological events.


Q: Does Peginterferon alfa-2b cause weight change?

Yes, official adverse reaction reports have included weight changes. Both decreased weight (weight loss) and weight gain have been reported in clinical trial settings.


Q: What happens in the body to break down Peginterferon alfa-2b?

Regulatory pharmacology information indicates that the drug is broken down, or metabolized, primarily through a process called hydrolysis of the PEG bond. This process releases the active interferon protein, which is then cleared from the body through metabolic pathways.


Q: Does Peginterferon alfa-2b cause mouth sores or dry mouth?

Dry mouth (xerostomia) has been officially reported as a side effect. Mouth sores are also sometimes reported with interferon-alpha products, but the frequency data specific to Peginterferon alfa-2b are limited.


Q: Are there non-drug-related factors that can affect how Peginterferon alfa-2b works?

Yes, regulatory information notes that the overall physiological response to the medicine is influenced by host genetic factors. For example, the IFNL3 genotype is noted as an element that can affect the signaling pathway induced by the medicine.


Q: How long does the Peginterferon alfa-2b stay in the system?

Due to the pegylation process, the medicine has an extended half-life compared to non-pegylated interferons, which is why it is dosed only once per week. Regulatory documents do not provide a specific number of days for final clearance, but its long half-life means it remains present for an extended period.


Q: What are the most common reasons patients stop Peginterferon alfa-2b therapy?

Clinical trial data indicate that a high rate of discontinuation was observed among patients due to adverse reactions experienced during the regimen. This suggests that the side effects and other effects observed during the course of therapy were the most common reason for not completing the planned duration of treatment.

Advertisements

How should Peginterferon alfa-2b be stored and disposed of?

How to Store and Dispose of Peginterferon alfa-2b

Storage Requirements

Product Form Storage Temperature Stability & Handling
Powder for Injection (Unmixed) Store at room temperature. Protect from heat.
Prefilled Pen (Redipen®) Store in the refrigerator (2 C to 8 C / 36 F to 46 F). Keep in the outer carton to protect from light. Do not freeze.
Reconstituted Solution Store in the refrigerator (2 C to 8 C / 36 F to 46 F). Use within 24 hours. Do not shake the vial during mixing; swirl gently. Discard if cloudy, discolored, or if particles are present.

Disposal Instructions

Dispose of all used needles, syringes, and vials immediately by placing them into an FDA-cleared sharps disposal container. Follow local community guidelines for the proper disposal of a full sharps container. Do not reuse any components or throw loose sharps into household trash or recycling. Keep out of the reach of children and pets.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Peginterferon alfa-2b found in:

A-Z Index: